BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 37819612)

  • 1. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
    Terkeltaub R
    Drugs; 2023 Nov; 83(16):1501-1521. PubMed ID: 37819612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and rationale for uricase use in patients with gout.
    Schlesinger N; Pérez-Ruiz F; Lioté F
    Nat Rev Rheumatol; 2023 Oct; 19(10):640-649. PubMed ID: 37684360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Safety of Urate Lowering Therapies.
    Kang EH; Kim SC
    Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gout].
    Tausche AK
    Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
    Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
    Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
    Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
    PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel uricosurics.
    Bardin T; Richette P
    Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i42-i46. PubMed ID: 29272511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    Bakris GL; Doghramji PP; Keenan RT; Silber SH
    Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
    Peeters IR; den Broeder AA; Taylor WJ; den Broeder N; Flendrie M; van Herwaarden N
    Trials; 2023 Apr; 24(1):282. PubMed ID: 37072799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gout].
    Tausche AK
    Z Rheumatol; 2022 Jun; 81(5):400-412. PubMed ID: 35596003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
    Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenges of gout management in the elderly.
    Stamp LK; Jordan S
    Drugs Aging; 2011 Aug; 28(8):591-603. PubMed ID: 21812496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare.
    Tai V; Gow P; Stewart S; Satpanich P; Li C; Abhishek A; Dalbeth N
    Semin Arthritis Rheum; 2024 Apr; 65():152367. PubMed ID: 38215627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.